In light of the UK government's about-turn on allowing patients to pay privately for medicines not covered under the National Health Service (Marketletter November 3 and page 12 this issue), private health insurers are considering launching a range of products fund these drugs, reports the Financial Times.
Although at present only WPA Health Insurance offers such a scheme, and then only for cancer agents, Bupa, AXA/PPP and Norwich Union Healthcare are looking at the issue, the newspaper notes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze